Next-generation Penta surgical lead showcased at the 13th Annual North
American Neuromodulation Society Meeting
ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 4, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced the U.S. Food and Drug
Administration (FDA) approval and U.S. market introduction of its new
Penta™ surgical lead for neurostimulation therapy. Unveiled at the
annual North American Neuromodulation Society meeting, the Penta lead is
the first of its kind, featuring the smallest electrodes in the market
arranged in five columns.
This innovative surgical lead provides the broadest lateral electrode
span of any neurostimulation lead on the market – yet the paddle
configuration is only 10.9 mm wide. The Penta lead’s unique design is
made possible by a proprietary micro-texturing process which enables
greater amounts of current to be delivered via the small electrodes. The
result is a lead that can more specifically focus current over a greater
lateral area of the spinal cord, which may provide better coverage for
managing hard to control chronic pain.
“The Penta lead provides surgeons with an innovative new approach to
increasing targeted control in managing chronic pain through
neurostimulation therapy,” said Chris Chavez, president of the St. Jude
Medical Neuromodulation Division. “We are proud to unveil this
next-generation surgical lead – yet another first-of-its-kind
technological advancement from St. Jude Medical.”
Neurostimulation therapy is used for managing chronic pain of the trunk
and limbs and pain from back surgeries that have failed. A lead is a
small insulated wire with multiple electrodes that is placed in the
epidural space near the spine. Mild electrical pulses are carried from
the neurostimulator to the lead’s electrodes to interrupt or mask the
transmission of pain signals to the brain. Electrodes on the lead can be
programmed to meet each individual patient’s needs.
Chronic pain affects millions of patients worldwide. In the U.S., more
than 76.5 million people are categorized as suffering from chronic pain
by the American Pain Foundation. Estimates by the National Institutes of
Health place the costs for lost work time and healthcare expenses at
approximately $100 billion every year.
More than 60,000 patients in 35 countries have been implanted with St.
Jude Medical neurostimulation systems. Patients can obtain more
information about neurostimulation pain therapies at www.PowerOverYourPain.com.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on
putting more control into the hands of those who treat cardiac,
neurological and chronic pain patients worldwide. The company is
dedicated to advancing the practice of medicine by reducing risk
wherever possible and contributing to successful outcomes for every
patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more
than 14,000 people worldwide and has four major focus areas that
include: cardiac rhythm management, atrial fibrillation, cardiovascular
and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the SEC, including those described in the Risk Factors and
Cautionary Statements sections of the Company’s Quarterly Reports on
Form 10-Q for the fiscal quarters ended April 4, 2009, July 4, 2009 and
October 3, 2009. The Company does not intend to update these statements
and undertakes no duty to any person to provide any such update under
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6113684&lang=en
Source: St. Jude Medical, Inc.
St. Jude Medical, Inc.
J.C. Weigelt, 651-756-4347